Acoziborole - Drugs for Neglected Diseases Initiative Foundation

Drug Profile

Acoziborole - Drugs for Neglected Diseases Initiative Foundation

Alternative Names: AN-5568; Oxaborole SCYX-7158; SCYX-7158

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anacor Pharmaceuticals; SCYNEXIS
  • Developer Drugs for Neglected Diseases Initiative Foundation
  • Class Antiprotozoals; Benzamides; Organic boron compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Trypanosomiasis

Most Recent Events

  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 08 Sep 2015 Anacor Pharmaceuticals and the Drugs for Neglected Diseases Initiative Foundation completes a phase I trial in Trypanosomiasis (In volunteers) in France
  • 08 Sep 2015 Drugs for Neglected Diseases Initiative Foundation and partners plans a pivotal phase IIb/III trial for Trypanosomiasis in Congo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top